| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8457667 | Nuclear Medicine and Biology | 2018 | 37 Pages |
Abstract
The bifunctional chelator NODIA-Me 1 was successfully conjugated to a PSMA targeting moiety. In small-animal PET imaging and ex vivo biodistribution studies, 68Ga- and 64Cu-labelled conjugates specifically delineated PSMA-positive LNCaP tumors and exhibited rapid renal clearance from non-target tissues with no significant demetallation/transchelation in vivo. The results support further development of this novel chelating platform for production of 68Ga- and 64Cu-labelled radiopharmaceuticals.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tilman Läppchen, Yvonne Kiefer, Jason P. Holland, Mark D. Bartholomä,